EMBr Wave for the Reduction of Hot Flashes in Women With a History of Breast Cancer

Inclusion Criteria:

* Women with history of breast cancer, ductal breast carcinoma in situ (DCIS), or lobular breast carcinoma in situ (LCIS) (currently without evidence of malignant disease)
* Bothersome hot flashes (defined by their occurrence of \>= 28 times per week and of sufficient severity to prompt the patient to seek therapeutic intervention)
* Presence of hot flashes for \> 30 days prior to study entry
* Ability to complete questionnaire(s) by themselves or with assistance
* Willingness to wear EMBr Wave device during the study period
* Willingness to use the EMBr Wave mobile application
* Have a working smartphone that can download the EMBr Wave mobile application (iPhone 6 or more recent generation, Android 8.0 or more recent generation)
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) = 0, 1
* Ability to provide informed written consent
* Life expectancy \>= 6 months

Exclusion Criteria:

* Antineoplastic chemotherapy (anti-HER2 agents allowed) (current \[=\< 4 weeks prior\] or planned therapy)
* Androgens (current \[=\< 4 weeks prior\] or planned therapy)
* Systemic estrogens. Local vaginal estrogen preparations are allowed, but need to have been initiated for vulvo-vaginal atrophy at least 28 days prior, and must not be expected to stop or change the dose or frequency of the medication during the study period (current \[=\< 4 weeks prior\] or planned therapy)
* Progestogens (current \[=\< 4 weeks prior\] or planned therapy)
* Tamoxifen, raloxifene and aromatase inhibitors are allowed, but patient must have been on a constant dose for at least 28 days and must not be expected to stop the medication during the study period (current \[=\< 4 weeks prior\] or planned therapy)
* Selective serotonin reuptate inhibitors (SSRIs)/serotonin-norepinephrine reuptake inhibitor (SNRIs), when being used for hot flash management or other indications such as depression, is allowed, assuming the dose will remain unchanged for the study duration (current \[=\< 4 weeks prior\] or planned therapy)
* Gabapentin/pregabalin, when being used for hot flash management (use for other indications, such as pain, is allowed, assuming the dose will remain unchanged for the study duration) (current \[=\< 4 weeks prior\] or planned therapy)
* Clonidine (current \[=\< 4 weeks prior\] or planned therapy)
* Prior use of EMBr Wave
* Nickel allergy
* Pregnant or nursing women since the safety of device has not been established in this population